RAPT Therapeutics $75 million follow-on offering
Davis Polk advised the joint book-running managers in connection with a $75 million SEC-registered follow-on offering of 4,054,055 shares of common stock by RAPT Therapeutics, Inc. The underwriters have been granted an option to purchase up to 608,108 additional shares. The common stock is listed on the Nasdaq Global Market under the symbol “RAPT.”
RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology.
The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Paula Gergen and Savannah J. Dowling. The intellectual property and technology transactions team included partner David R. Bauer and associate Mikaela Dealissia. The tax team included partner Kara L. Mungovan and associate Eitan Ulmer. Members of the Davis Polk team are based in the Northern California and New York offices.